Pacira Pharma (PCRX) Tops Q2 EPS by 7c

Pacira Pharma (NASDAQ: PCRX) reported Q2 EPS of $0.27, $0.07 better than the analyst estimate of $0.20. Revenue for the quarter came in at $58.3 million versus the consensus estimate of $61.1 million.

EXPAREL net product revenues were $56.0 million in the first quarter of 2015, compared to $34.4 million in the first quarter of 2014.

For earnings history and earnings-related data on Pacira Pharma (PCRX) click here.

You May Also Be Interested In

• MillerKnoll, Inc. (MLKN) Tops Q1 EPS by 18c ; Offers Guidance
• CRH plc (CRH) PT Lowered to $135 at UBS, Buy Rating Maintained
• UBS Reiterates Neutral Rating on Pilgrim's Pride (PPC) on 'Challenging' Near-Term Fundamentals